Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Advanced CRC: Liquid Biopsies and the CRICKET Study

June 20th 2018

VALENTINO Study: Maintenance Therapy in Advanced CRC

June 20th 2018

Combination Strategies in Advanced CRC: E7208 and APOLLON

June 20th 2018

Key Investigations in Advanced Colorectal Cancer

June 20th 2018

Dr. Bekaii-Saab on Immunotherapy in Colorectal Cancer

June 18th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of immunotherapy in patients with microsatellite stable colorectal cancer.

Adjuvant Chemotherapy Advances Boost Outcomes in GI Malignancies

June 18th 2018

Diane Reidy-Lagunes, MD, outlines the current state-of-the-art gastrointestinal care.

Patients Aged

June 13th 2018

Patients younger than 65 years experienced net cancer costs that were higher for breast, colorectal, lung, and prostate cancer compared with patients who were 65 years and older.

Status Report: Expert Reviews Guideline-Based Options in Advanced CRC

June 13th 2018

There are pivotal developments in colorectal cancer that have shaped the National Comprehensive Cancer Network guidelines in the past several years.

It's Not Quite Prime Time for Up-Front Genomic Sequencing in Early-Stage CRC

June 11th 2018

Although testing for some genetic defects has been incorporated into the treatment paradigm, the clinical utility of up-front tumor sequencing that would yield wide-ranging information has not yet been established.

Heated Chemo During Resection Shows No Benefit in Advanced CRC

June 4th 2018

The addition of heated chemotherapy delivered to the abdomen during surgery delivered no survival benefit to patients with peritoneal carcinomatosis.

Colorectal Cancer Treatment Twice as Costly in US Than Canada, Despite Similar Outcomes

June 2nd 2018

A study that compared costs of treatment for metastatic colorectal cancer in Western Washington and the province of British Columbia in Canada found that prices were more than twice as high for the US patients than for their Canadian counterparts, with no significant difference in outcomes.

ASCO 2018: Top Oncologists Select Key, Practice-Changing Abstracts

May 30th 2018

Key opinion leaders spoke with OncLive ahead of the 2018 ASCO Annual Meeting to share the top abstracts they believe could have the greatest impact on clinical practice and patient outcomes across lymphomas, gastrointestinal cancers, genitourinary cancers, and lung cancer.

Dr. Atreya Discusses Maintenance Therapy for CRC

May 29th 2018

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses maintenance therapy for patients with colorectal cancer.

Dr. Kopetz Discusses Triplet Therapy for BRAF-Mutant CRC

May 25th 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses triplet therapy for patients with BRAF-mutant colorectal cancer

Dr. Bekaii-Saab on the Use of Regorafenib in Patients With mCRC

May 24th 2018

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Atezolizumab, Cobimetinib Combo Falls Short in Phase III mCRC Trial

May 10th 2018

Combination therapy with the PD-L1 inhibitor atezolizumab and the MEK inhibitor cobimetinib failed to improve overall survival versus regorafenib in previously treated patients with locally advanced or metastatic colorectal cancer, according to topline findings from the phase III IMblaze370 study.

Marshall Highlights Durable Benefits of Pembrolizumab in GI Cancers

May 3rd 2018

Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.

Dr. Atreya on Questions Remaining With Tumor Sidedness in CRC

April 25th 2018

Chloe E. Atreya, MD, PhD, assistant clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses questions regarding sidedness in colorectal cancer.

Dr. Kopetz Discusses the Treatment of BRAF-Mutant CRC

April 21st 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with BRAF-mutant colorectal cancer.

Dr. Bhoola on Enhanced Recovery After Surgery in Gynecologic Cancer

April 12th 2018

Snehal Bhoola, MD, assistant professor, Mercer University School of Medicine, associate professor, University of Arizona, Arizona Oncology, discusses enhanced recovery after surgery (ERAS) in gynecologic malignancies.